# Ultragenyx Pharmaceutical Inc.: financial statements, quarterly

RARE · Nasdaq · CIK 1515673 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rare.md) · [Financials](/companies/rare/financials.md) · [Filings](/companies/rare/filings.md) · [Insiders](/companies/rare/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rare/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [98.1](/filings/0000950170-24-121679.md) | [127 d](/filings/0001193125-26-057329.md) | [109](/filings/0000950170-25-064726.md) | [147](/filings/0000950170-25-103290.md) | [139](/filings/0001193125-25-265126.md) | [165 d](/filings/0001193125-26-057329.md) | [139](/filings/0001193125-26-206960.md) | [167](/filings/0001193125-26-333233.md) | [160](/filings/0001193125-25-265126.md) | [207 d](/filings/0001193125-26-057329.md) | [136](/filings/0001193125-26-206960.md) | [214](/filings/0001193125-26-333233.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [157](/filings/0000950170-24-121679.md) | [160 d](/filings/0001193125-26-057329.md) | [178](/filings/0000950170-25-064726.md) | [162](/filings/0000950170-25-103290.md) | [170](/filings/0001193125-25-265126.md) | [188 d](/filings/0001193125-26-057329.md) | [166](/filings/0001193125-26-206960.md) | [165](/filings/0001193125-26-333233.md) | [216](/filings/0001193125-25-265126.md) | [203 d](/filings/0001193125-26-057329.md) | [187](/filings/0001193125-26-206960.md) | [167](/filings/0001193125-26-333233.md) |
| Selling, general and administrative | $m | [74.9](/filings/0000950170-24-121679.md) | [77.0 d](/filings/0001193125-26-057329.md) | [78.2](/filings/0000950170-25-064726.md) | [80.6](/filings/0000950170-25-103290.md) | [80.4](/filings/0001193125-25-265126.md) | [81.9 d](/filings/0001193125-26-057329.md) | [87.0](/filings/0001193125-26-206960.md) | [87.0](/filings/0001193125-26-333233.md) | [86.6](/filings/0001193125-25-265126.md) | [87.9 d](/filings/0001193125-26-057329.md) | [88.0](/filings/0001193125-26-206960.md) | [88.0](/filings/0001193125-26-333233.md) |
| Operating income | $m | [(145)](/filings/0000950170-24-121679.md) | [(122) d](/filings/0001193125-26-057329.md) | [(165)](/filings/0000950170-25-064726.md) | [(116)](/filings/0000950170-25-103290.md) | [(132)](/filings/0001193125-25-265126.md) | [(122) d](/filings/0001193125-26-057329.md) | [(143)](/filings/0001193125-26-206960.md) | [(108)](/filings/0001193125-26-333233.md) | [(171)](/filings/0001193125-25-265126.md) | [(113) d](/filings/0001193125-26-057329.md) | [(169)](/filings/0001193125-26-206960.md) | [(75.0)](/filings/0001193125-26-333233.md) |
| Income tax | $m | [0.7](/filings/0000950170-24-121679.md) | [(3.9) d](/filings/0001193125-26-057329.md) | [0.5](/filings/0000950170-25-064726.md) | [0.9](/filings/0000950170-25-103290.md) | [0.3](/filings/0001193125-25-265126.md) | [0.4 d](/filings/0001193125-26-057329.md) | [1.0](/filings/0001193125-26-206960.md) | [1.0](/filings/0001193125-26-333233.md) | [0.9](/filings/0001193125-25-265126.md) | [0.9 d](/filings/0001193125-26-057329.md) | [1.0](/filings/0001193125-26-206960.md) | [1.0](/filings/0001193125-26-333233.md) |
| Net income | $m | [(160)](/filings/0000950170-24-121679.md) | [(124) d](/filings/0001193125-26-057329.md) | [(171)](/filings/0000950170-25-064726.md) | [(132)](/filings/0000950170-25-103290.md) | [(134)](/filings/0001193125-25-265126.md) | [(133) d](/filings/0001193125-26-057329.md) | [(151)](/filings/0001193125-26-206960.md) | [(115)](/filings/0001193125-26-333233.md) | [(180)](/filings/0001193125-25-265126.md) | [(129) d](/filings/0001193125-26-057329.md) | [(185)](/filings/0001193125-26-206960.md) | [(92.0)](/filings/0001193125-26-333233.md) |
| Diluted EPS | $ per share | [(2.23)](/filings/0000950170-24-121679.md) | not reported | [(2.03)](/filings/0000950170-25-064726.md) | [(1.52)](/filings/0000950170-25-103290.md) | [(1.40)](/filings/0001193125-25-265126.md) | not reported | [(1.57)](/filings/0001193125-26-206960.md) | [(1.17)](/filings/0001193125-26-333233.md) | [(1.81)](/filings/0001193125-25-265126.md) | not reported | [(1.84)](/filings/0001193125-26-206960.md) | [(0.90)](/filings/0001193125-26-333233.md) |
| Basic EPS | $ per share | [(2.23)](/filings/0000950170-24-121679.md) | not reported | [(2.03)](/filings/0000950170-25-064726.md) | [(1.52)](/filings/0000950170-25-103290.md) | [(1.40)](/filings/0001193125-25-265126.md) | not reported | [(1.57)](/filings/0001193125-26-206960.md) | [(1.17)](/filings/0001193125-26-333233.md) | [(1.81)](/filings/0001193125-25-265126.md) | not reported | [(1.84)](/filings/0001193125-26-206960.md) | [(0.90)](/filings/0001193125-26-333233.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [72.6](/filings/0000950170-24-121679.md) | [214](/filings/0001193125-26-057329.md) | [112](/filings/0000950170-25-064726.md) | [481](/filings/0000950170-25-103290.md) | [151](/filings/0001193125-25-265126.md) | [174](/filings/0001193125-26-057329.md) | [127](/filings/0001193125-26-206960.md) | [176](/filings/0001193125-26-333233.md) | [203](/filings/0001193125-25-265126.md) | [421](/filings/0001193125-26-333233.md) | [175](/filings/0001193125-26-206960.md) | [125](/filings/0001193125-26-333233.md) |
| Current assets | $m | [599](/filings/0000950170-23-058427.md) | [732](/filings/0000950170-25-023312.md) | [596](/filings/0000950170-24-052346.md) | [965](/filings/0000950170-24-089488.md) | [800](/filings/0000950170-24-121679.md) | [817](/filings/0001193125-26-057329.md) | [699](/filings/0000950170-25-064726.md) | [720](/filings/0000950170-25-103290.md) | [643](/filings/0001193125-25-265126.md) | [951](/filings/0001193125-26-333233.md) | [657](/filings/0001193125-26-206960.md) | [606](/filings/0001193125-26-333233.md) |
| Total assets | $m | [1,238](/filings/0000950170-23-058427.md) | [1,491](/filings/0000950170-25-023312.md) | [1,307](/filings/0000950170-24-052346.md) | [1,618](/filings/0000950170-24-089488.md) | [1,538](/filings/0000950170-24-121679.md) | [1,503](/filings/0001193125-26-057329.md) | [1,312](/filings/0000950170-25-064726.md) | [1,306](/filings/0000950170-25-103290.md) | [1,190](/filings/0001193125-25-265126.md) | [1,532](/filings/0001193125-26-333233.md) | [1,296](/filings/0001193125-26-206960.md) | [1,264](/filings/0001193125-26-333233.md) |
| Current liabilities | $m | [254](/filings/0000950170-23-058427.md) | [280](/filings/0000950170-25-023312.md) | [246](/filings/0000950170-24-052346.md) | [273](/filings/0000950170-24-089488.md) | [285](/filings/0000950170-24-121679.md) | [344](/filings/0001193125-26-057329.md) | [292](/filings/0000950170-25-064726.md) | [293](/filings/0000950170-25-103290.md) | [340](/filings/0001193125-25-265126.md) | [384](/filings/0001193125-26-333233.md) | [325](/filings/0001193125-26-206960.md) | [351](/filings/0001193125-26-333233.md) |
| Total liabilities | $m | [1,206](/filings/0000950170-23-058427.md) | [1,216](/filings/0000950170-25-023312.md) | [1,167](/filings/0000950170-24-052346.md) | [1,186](/filings/0000950170-24-089488.md) | [1,185](/filings/0000950170-24-121679.md) | [1,241](/filings/0001193125-26-057329.md) | [1,161](/filings/0000950170-25-064726.md) | [1,148](/filings/0000950170-25-103290.md) | [1,174](/filings/0001193125-25-265126.md) | [1,605](/filings/0001193125-26-333233.md) | [1,525](/filings/0001193125-26-206960.md) | [1,548](/filings/0001193125-26-333233.md) |
| Shareholders' equity | $m | [31.7](/filings/0000950170-24-121679.md) | [275](/filings/0001193125-26-057329.md) | [140](/filings/0000950170-25-103290.md) | [432](/filings/0001193125-25-265126.md) | [347](/filings/0001193125-25-265126.md) | [255](/filings/0001193125-26-333233.md) | [144](/filings/0001193125-26-333233.md) | [151](/filings/0001193125-26-333233.md) | [9.2](/filings/0001193125-25-265126.md) | [(80.0)](/filings/0001193125-26-333233.md) | [(236)](/filings/0001193125-26-333233.md) | [(291)](/filings/0001193125-26-333233.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(118) d](/filings/0000950170-24-121679.md) | [(84.1) d](/filings/0001193125-26-057329.md) | [(191)](/filings/0000950170-25-064726.md) | [(77.0) d](/filings/0000950170-25-103290.md) | [(67.0) d](/filings/0001193125-25-265126.md) | [(79.3) d](/filings/0001193125-26-057329.md) | [(166)](/filings/0001193125-26-206960.md) | [(109) d](/filings/0001193125-26-333233.md) | [(91.2) d](/filings/0001193125-25-265126.md) | [(99.8) d](/filings/0001193125-26-057329.md) | [(197)](/filings/0001193125-26-206960.md) | [(97.0) d](/filings/0001193125-26-333233.md) |
| Capital expenditure | $m | [3.7 d](/filings/0000950170-24-121679.md) | [1.3 d](/filings/0001193125-26-057329.md) | [3.2](/filings/0000950170-25-064726.md) | [2.0 d](/filings/0000950170-25-103290.md) | [1.6 d](/filings/0001193125-25-265126.md) | [0.2 d](/filings/0001193125-26-057329.md) | [1.0](/filings/0001193125-26-206960.md) | [3.0 d](/filings/0001193125-26-333233.md) | [1.1 d](/filings/0001193125-25-265126.md) | [0.9 d](/filings/0001193125-26-057329.md) | [1.0](/filings/0001193125-26-206960.md) | [1.0 d](/filings/0001193125-26-333233.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [70.1](/filings/0000950170-23-058427.md) | [70.4](/filings/0000950170-24-052346.md) | [70.9](/filings/0000950170-24-089488.md) | [71.7](/filings/0000950170-24-121679.md) | [84.3](/filings/0000950170-25-064726.md) | [86.6](/filings/0000950170-25-103290.md) | [95.5](/filings/0001193125-25-265126.md) | [96.3](/filings/0001193125-26-206960.md) | [98.5](/filings/0001193125-26-333233.md) | [99.8](/filings/0001193125-25-265126.md) | [101](/filings/0001193125-26-206960.md) | [102](/filings/0001193125-26-333233.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 98,588,873 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333233.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.